Meeting unmet medical needs through distinctive scientific capabilities.

Innovation at Glenmark

Innovation is at the heart of everything that we at Glenmark do – from discovering novel molecules, to manufacturing effective medicines to the way we operate. Our drug discovery endeavors focus on the therapeutic areas of dermatology, pain / inflammation and oncology. Our distinctive scientific capabilities have enabled us to build a strong pipeline of several first-in-class molecules - both NCEs (New Chemical Entities) and NBEs (New Biological Entities).  We have also made a mark in this area by successfully out-licensing seven of our own molecules to large multinationals.

Our prudent strategy for innovation has helped us to emerge as a leading integrated research-based organization. Our R&D centers are well equipped to research and develop novel molecules by combining cutting-edge technology, state-of-the-art infrastructure, and the brightest minds. The R&D team comprises of over 800 scientists across 5 R&D centers in India and Switzerland with a commitment to identify cures for unmet needs that matter most. Glenmark’s scientists have also invented a propriety best-in-class technology platform to manufacture bispecific antibodies, BEAT®.Visit the BEAT®platform